The 2026 picture: huge demand, rationed supply
GLP-1 weight-loss injections are the most talked-about medicines of the decade, and in 2026 two facts dominate every conversation about them: they work, and they are hard to get. In the UK the NHS funds them only through a tightly staged rollout. In the US they are available faster but the cash price stops most people in their tracks. Underneath both systems is the same pressure — far more people want these drugs than any health service or budget can currently absorb.
This guide is a neutral reference on where things actually stand: who the NHS covers in 2026, what private and US cash prices look like, and why the next-generation molecule everyone is reading about — retatrutide — is not in pharmacies at all yet.
Mounjaro on the NHS: a phased rollout, not open access
From 1 April 2026, NHS England incorporated tirzepatide (Mounjaro) prescribing into the 2026/27 GP contract through new Quality and Outcomes Framework (QOF) indicators. Importantly, GP practices are not mandated to prescribe it, so availability varies from practice to practice. Access is being widened in stages:
| Phase | From | Who becomes eligible |
|---|---|---|
| Phase 1 | Now (2026) | BMI 40+ (ethnicity-adjusted) with 4 of 5 weight-related conditions |
| Phase 2 | ~June 2026 | BMI 35+ with 4 of 5 weight-related conditions |
| Phase 3 | April 2027 | BMI 40+ with 3 of 5 weight-related conditions |
NICE has set out a phased launch lasting up to 12 years, with roughly 220,000 people expected to receive the injection in the first three years. Meeting the criteria does not guarantee treatment — prescribing still depends on local service capacity and a clinical assessment, and patients must agree to take part in a "wraparound" support programme alongside the medication.
Wegovy on the NHS: tier-3 specialist services
Wegovy (semaglutide) follows a different door. A GP refers you to a tier-3 specialist weight-management service, and eligibility generally requires a BMI of 35+ (or 32.5+ for people of Asian, Chinese, Middle Eastern, Black African or African-Caribbean origin) together with weight-related health problems — or a lower BMI band (30–34.9, or 27.5–32.4 with ethnicity adjustment) if you meet specific criteria for specialist treatment. As with Mounjaro, the practical bottleneck is geography and waiting lists: where you live changes whether you can access it at all.
What it costs if you pay yourself
For everyone outside the NHS gates, the route is private — and the price tag is the reason the topic dominates forums.
| Option | Approx. monthly cost | Notes |
|---|---|---|
| Private UK online pharmacy | ≈ £150–£250 | Dose-dependent; not NHS-funded |
| Mounjaro US list price | ≈ $1,069 / 28 days | Retail cash often $995–$1,300 |
| Wegovy US list price | ≈ $1,846 | NovoCare cash price ≈ $349/month |
| Zepbound (tirzepatide, weight loss) | from ≈ $349/month | LillyDirect self-pay, single-dose vials |
Even the discounted direct-to-consumer cash prices ($349/month) add up to several thousand dollars a year, and the full list prices are out of reach for most households. That gap between demand and affordability is exactly what has pushed so many people to look for alternatives.
Where retatrutide fits — and why it isn’t at the pharmacy
Retatrutide is the molecule the headlines keep returning to. It is a triple GLP-1/GIP/glucagon agonist, and its Phase 3 TRIUMPH-1 readout (announced May 2026) reported the largest weight reduction ever recorded in a Phase 3 obesity trial — a result discussed in detail in our retatrutide science reference. But the regulatory clock is slow: the NDA is expected in Q4 2026, FDA approval not before late 2027, and a commercial launch around 2028. There is therefore no licensed retatrutide, no NHS funding for it, and no pharmacy price — only an 18-to-24-month wait while demand keeps climbing.
At the same time, the FDA moved in May 2026 to close large-scale compounding of GLP-1 drugs, removing the cheaper semi-legal route that many people had relied on. The combined effect — a record-breaking molecule years from market, and the budget route shutting — is the structural shift covered in our analysis of the GLP-1 compounding ban.
The research route, stated plainly
This is where research-grade peptides enter the conversation. They are lyophilized reagents sold strictly for laboratory and in-vitro work — never for human use, and with no medical claims attached. They are how a laboratory legitimately obtains a compound like retatrutide that has no consumer licence. They are not a prescription medicine, not a treatment, and not a way around the NHS or a doctor.
What a research setting does require is characterised material: documented purity, a Certificate of Analysis, correct reconstitution and storage. Those standards — and how to read a COA — are covered in the complete research peptides guide, with the concentration math in our reconstitution guide.